Fennec Pharmaceuticals Inc.
FENCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Fennec Pharmaceuticals Inc. (FENC) is listed under Biotechnology. With a market capitalization of $434.5M, it sits in small-cap territory. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.
Market Cap
$434.5M
Beta
1.10
P/E (TTM)
—
P/E (Fwd)
13.01
EPS (TTM)
$-0.12
EPS (Fwd)
$0.95
ROE
-18.6%
ROA
-1.2%
Cash
$41.2M
Total Debt
$0
Free CF
$1.1M
52W Change
34.4%
Annual Financials
Cash vs Debt
Where FENC stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, FENC finished 35.78% above its 150-day moving average ($8.86) and 40.37% above its 200-day moving average ($8.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FENC overbought or oversold?
At the September 2, 2026 close, FENC's RSI(14) was 52.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Fennec Pharmaceuticals Inc. reports $41.2M in cash and $0 in total debt. The company generates $1.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -18.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.5M (2022) to $44.6M (2025), reflecting a 2808% increase over the period.
Investors considering Fennec Pharmaceuticals Inc. should weigh the typical risks associated with FENC's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fennec Pharmaceuticals Inc. and its sector.